Patents by Inventor Edwin Chang

Edwin Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11529511
    Abstract: Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: December 20, 2022
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Novocure GmbH
    Inventors: Edwin Chang, Chirag B. Patel, Sanjiv S. Gambhir, Tali Voloshin-Sela, Yaara Porat, Moshe Giladi
  • Publication number: 20210199640
    Abstract: Viability of cancer cells (e.g., glioblastoma cells) can be reduced by administering mannose to the cancer cells; and applying an alternating electric field with a frequency between 100 and 500 kHz to the cancer cells. Susceptibility to treatment with an alternating electric field can be determined by measuring uptake of a PKM2 probe (e.g., [18F]DASA) before and after treatment with an alternating electric field. Notably, experiments show that the combination of mannose and the alternating electric field produces a synergistic anti-glioblastoma result.
    Type: Application
    Filed: December 24, 2020
    Publication date: July 1, 2021
    Inventors: Chirag Bihesh PATEL, Corinne G. Beinat, Edwin Chang, Sanjiv Sam Gambhir, Arutselvan Natarajan
  • Publication number: 20200254242
    Abstract: Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Inventors: Edwin CHANG, Chirag B. PATEL, Sanjiv S. GAMBHIR, Tali VOLOSHIN-SELA, Yaara PORAT, Moshe GILADI
  • Publication number: 20200121728
    Abstract: In the context of a stem cell-based therapy in which differentiated cells are derived from pluripotent stem cells, this application discloses approaches for eliminating residual pluripotent stem cells that may remain in a batch of differentiated progeny cells. This advantageously prevents the formation of teratoma tumors when the differentiated cells are eventually used for the therapy. This can be accomplished by exposing the batch of differentiated progeny cells and the residual pluripotent stem cells to an alternating electric field for a period of time. The frequency and field strength of the alternating electric field are such that the pluripotent stem cells die off as a result of exposure to the alternating electric fields, while the differentiated cells remain substantially unharmed. This results in a purified batch of differentiated progeny cells that is rendered safe for use in the stem cell-based therapy.
    Type: Application
    Filed: October 23, 2019
    Publication date: April 23, 2020
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mirwais WARDAK, Edwin CHANG, Joseph C. WU, Sanjiv Sam GAMBHIR
  • Publication number: 20200009376
    Abstract: Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).
    Type: Application
    Filed: July 3, 2019
    Publication date: January 9, 2020
    Inventors: Edwin CHANG, Chirag B. PATEL, Sanjiv S. GAMBHIR, Tali VOLOSHIN-SELA, Yaara PORAT, Moshe GILADI
  • Publication number: 20200009377
    Abstract: Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).
    Type: Application
    Filed: July 3, 2019
    Publication date: January 9, 2020
    Inventors: Edwin CHANG, Chirag B. PATEL, Sanjiv S. GAMBHIR, Tali VOLOSHIN-SELA, Yaara PORAT, Moshe GILADI
  • Patent number: 9659396
    Abstract: Simulating cloth garments can be a large challenge that requires both directability as well as stability. In various embodiments, cloth garments can be animated using a technique called “Clothwarp.” Clothwarp assists garment animation through methods of cloth articulation and simulation targeting. In one aspect, Clothwarp grants another level of directable control on simulation, allowing the artist to modify the influence of the warp, both as a target input into the simulation and as a cleanup tool on simulation results.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 23, 2017
    Assignee: Pixar
    Inventors: Edwin Chang, Chris Griffin, David Lally
  • Patent number: 9588122
    Abstract: The present disclosure provides methods of treating cancer and modifying a cancer treatment for a cancer with an anti-EGFR drug by creating PRDX6 expression profiles and using the profiles to evaluate and optionally modify treatment. The present disclosure also provides assays and systems for assessing sensitivity of a cancer to an anti-EGFR therapy.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 7, 2017
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Edwin Chang, Lingyun Xu, Nick Hughes, Carsten H. Nielsen, Sanjiv S. Gambhir, Parag Mallick, Arutselvan Natarajan
  • Publication number: 20140275073
    Abstract: The present disclosure provides methods of treating cancer and modifying a cancer treatment for a cancer with an anti-EGFR drug by creating PRDX6 expression profiles and using the profiles to evaluate and optionally modify treatment. The present disclosure also provides assays and systems for assessing sensitivity of a cancer to an anti-EGFR therapy.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: Edwin Chang, Lingyun Xu, Nick Hughes, Carsten H. Nielsen, Sanjiv S. Gambhir, Parag Mallick, Arutselvan Natarajan
  • Patent number: 8236772
    Abstract: The present invention provides methods of modulating angiogenesis in an individual, as well as methods of identifying a candidate agent that modulates angiogenesis, where such methods involve modulating and identifying agents that modulate expression of gene products of a subset of genes concordantly-regulated by agonists of nicotinic acetylcholine receptor (nAChR), bFGF receptor, and VEGF receptor.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: August 7, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John P. Cooke, Martin Ng, Jenny C. Wu, Edwin Chang
  • Publication number: 20070135369
    Abstract: The present invention provides methods of modulating angiogenesis in an individual, as well as methods of identifying a candidate agent that modulates angiogenesis, where such methods involve modulating and identifying agents that modulate expression of gene products of a subset of genes concordantly-regulated by agonists of nicotinic acetylcholine receptor (nAChR), bFGF receptor, and VEGF receptor.
    Type: Application
    Filed: September 15, 2006
    Publication date: June 14, 2007
    Inventors: John Cooke, Martin Ng, Jenny Wu, Edwin Chang